Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group.
Journal
HemaSphere
ISSN: 2572-9241
Titre abrégé: Hemasphere
Pays: United States
ID NLM: 101740619
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
received:
09
02
2021
accepted:
11
05
2021
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
29
6
2021
Statut:
epublish
Résumé
The German study groups, the German Low-Grade Lymphoma Study Group (GLSG) and Ostdeutsche Studiengruppe Hämatologie und Onkologie (OSHO), initiated in 2007 a double randomized trial to investigate efficacy and safety of rituximab maintenance versus observation in remission after randomly assigned induction treatment in the first-line follicular lymphoma. Previously untreated patients with stage II-IV follicular lymphoma in need of therapy were randomized to receive 6 cycles of R-CHOP, R-MCP, or R-FCM. Responding patients were subsequently randomized to 2 years rituximab maintenance or observation, stratified by type of immunochemotherapy, quality of remission, and Follicular Lymphoma International Prognostic Index (FLIPI). Recruitment was stopped in 2011 after the PRIMA results had been published. Median age of the 206 recruited patients was 66 years (range, 24-86), and (FLIPI) was low in 13%, intermediate in 28%, and high in 60%. High and comparable overall response rates were observed after R-CHOP (88%), R-MCP (89%), and R-FCM (91%). Rituximab maintenance substantially prolonged progression-free survival (PFS) in comparison to observation in remission (hazard ratio 0.39,
Identifiants
pubmed: 34179697
doi: 10.1097/HS9.0000000000000600
pmc: PMC8221804
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e600Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
Références
Ann Oncol. 1998 Jul;9(7):717-20
pubmed: 9739436
PLoS One. 2017 May 11;12(5):e0177204
pubmed: 28493986
J Clin Oncol. 2013 Apr 20;31(12):1506-13
pubmed: 23530110
Eur J Cancer. 2017 May;76:216-225
pubmed: 28336303
J Clin Oncol. 2019 Apr 20;37(12):984-991
pubmed: 30811293
Blood. 2008 Dec 15;112(13):4824-31
pubmed: 18799723
J Clin Oncol. 2008 Oct 1;26(28):4579-86
pubmed: 18662969
Ann Oncol. 2016 Sep;27(suppl 5):v83-v90
pubmed: 27664263
Blood. 2014 May 8;123(19):2944-52
pubmed: 24591201
Cancer. 2016 Oct;122(19):2996-3004
pubmed: 27351685
J Clin Oncol. 2007 May 20;25(15):1986-92
pubmed: 17420513
Control Clin Trials. 1992 Apr;13(2):106-21
pubmed: 1316826
Blood. 2004 Nov 15;104(10):3064-71
pubmed: 15284112
Blood. 2005 Dec 1;106(12):3725-32
pubmed: 16123223
J Clin Oncol. 1997 Mar;15(3):1110-7
pubmed: 9060552
Blood. 2006 Nov 15;108(10):3295-301
pubmed: 16873669
Leukemia. 2020 Feb;34(2):522-532
pubmed: 31462735
Br J Haematol. 2013 Nov;163(4):487-95
pubmed: 24111533
J Clin Oncol. 2015 Aug 10;33(23):2516-22
pubmed: 26124482
Semin Oncol. 1993 Oct;20(5 Suppl 5):75-88
pubmed: 8211209
J Clin Oncol. 1999 Apr;17(4):1244
pubmed: 10561185
Clin Cancer Res. 2014 Dec 15;20(24):6398-405
pubmed: 25316810
J Clin Oncol. 1995 Jan;13(1):140-7
pubmed: 7799014
J Clin Oncol. 2019 Nov 1;37(31):2815-2824
pubmed: 31339826
J Clin Oncol. 2005 Feb 20;23(6):1088-95
pubmed: 15657401
Blood. 2016 Aug 25;128(8):1112-20
pubmed: 27418643
J Clin Oncol. 2009 Apr 1;27(10):1607-14
pubmed: 19255334
J Clin Oncol. 2018 Mar 1;36(7):689-696
pubmed: 29095677
Blood. 1997 Jun 1;89(11):3909-18
pubmed: 9166827
Lancet. 2011 Jan 1;377(9759):42-51
pubmed: 21176949
Am J Hematol. 2016 Nov;91(11):1096-1101
pubmed: 27465588
Br J Haematol. 2008 May;141(5):631-40
pubmed: 18422779
Blood. 2004 Jun 15;103(12):4416-23
pubmed: 14976046
J Clin Oncol. 2019 Jan 10;37(2):144-152
pubmed: 30481079